(v) R WING A/ICE LO HEAT (Caution): 30 R WING A/ICE LO HEAT—CTRL TEMP INOP (Info).

(vi) R WING A/ICE LO HEAT (Caution): 30 R WING A/ICE LO HEAT—R HPV FAIL CLSD (Info).

(vii) R WING A/ICE LO HEAT (Caution): 30 R WING A/ICE LO HEAT—R WING A/ICE TEMP SNSR INOP (Info).

(viii) R WING A/ICE OVHT (Caution): 30 R WING A/ICE OVHT—R WING—A/ICE TEMP SNSR INOP (Info).

(ix) WING A/ICE FAULT (Advisory): 30 WING A/ICE FAULT—L WING A/ICE VLV LEAK (Info).

(x) WING A/ICE FAULT (Advisory): 30 WING A/ICE FAULT—R WING A/ICE VLV LEAK (Info).

(xi) AIR SYSTEM FAULT (Advisory): 36 AIR SYSTEM FAULT—L BLEED MON PRESS SNSR INOP (Info).

(xii) AIR SYSTEM FAULT (Advisory): 36 AIR SYSTEM FAULT—R BLEED MON PRESS SNSR INOP (Info).

(xiii) L BLEED FAIL (Caution): 36 L BLEED FAIL—L BLEED TEMP SNSR INOP (Info).

(xiv) L BLEED FAIL (Caution): 36 L BLEED FAIL—L HPV FAIL CLSD (Info).

(xv) L BLEED FAIL (Caution): 36 L BLEED FAIL—L PRESS REG SOV INOP (Info).

(xvi) R BLEED FAIL (Caution): 36 R BLEED FAIL—R BLEED TEMP SNSR INOP (Info).

(xvii) R BLEED FAIL (Caution): 36 R BLEED FAIL—R HPV FAIL CLSD (Info).

(xviii) R BLEED FAIL (Caution): 36 R BLEED FAIL—R PRESS REG SOV INOP (Info).

(h) Additional AD Provisions

The following provisions also apply to this AD:

(1) *Alternative Methods of Compliance (AMOCs):* The Manager, AIR–520, Continued Operational Safety Branch, FAA, has the authority to approve AMOCs for this AD, if requested using the procedures found in 14 CFR 39.19. In accordance with 14 CFR 39.19, send your request to your principal inspector or responsible Flight Standards Office, as appropriate. If sending information directly to the manager of the Continued Operational Safety Branch, send it to the attention of the person identified in paragraph (i) of this AD and email to: *AMOC@faa.gov*. Before using any approved AMOC, notify your appropriate principal inspector, or lacking a principal inspector, the manager of the responsible Flight Standards Office.

(2) *Contacting the Manufacturer:* For any requirement in this AD to obtain instructions from a manufacturer, the instructions must be accomplished using a method approved by the Manager, AIR–520, Continued Operational Safety Branch, FAA; or Transport Canada; or Airbus Canada Limited Partnership's Transport Canada Design Approval Organization (DAO). If approved by the DAO, the approval must include the DAO-authorized signature.

(i) Additional Information

For more information about this AD, contact Michael Bumbaugh, Aviation Safety Engineer, FAA, 2200 South 216th St., Des Moines, WA 98198; phone: 206–231–3522; email: *Michael.Bumbaugh@faa.gov*.

(j) Material Incorporated by Reference

None.

Issued on July 1, 2026.

Brian Knaup,

Acting Deputy Director, Integrated Certificate Management Division, Aircraft Certification Service.

[FR Doc. 2026–13655 Filed 7–2–26; 11:15 am]

BILLING CODE 4910–13–P

DEPARTMENT OF TRANSPORTATION

Office of the Secretary

14 CFR Parts 260 and 399

[Docket No. DOT–OST–2022–0089, DOT–OST–2025–2285]

RIN 2105–AF04, 2105–AF36

Airline Refunds and Other Consumer Protections

AGENCY: Office of the Secretary of Transportation (OST), U.S. Department of Transportation.

ACTION: Notification of enforcement discretion.

SUMMARY: The U.S. Department of Transportation (Department or DOT) is extending its current enforcement discretion, announced on December 5, 2025, regarding specific refund regulations. Under current regulations, a flight assigned a different flight number than was active at the time of ticket purchase is considered a ''cancelled flight,'' making the consumer eligible for a prompt refund and related notifications. The Department is extending its discretion to not enforce these requirements for renumbered flights, provided that the passenger is rebooked on a flight with a new number and the flight operates without any ''significant change or delay'' as defined in its regulations. This extension provides the Department with the necessary time to complete the pending rulemaking addressing the definition of a flight cancellation.

DATES: As of July 7, 2026, the Department is extending the pause on the enforcement of airline refunds requirements regarding cancelled flights under 14 CFR parts 260 and 399 for flights that are merely renumbered. This enforcement discretion is extended for 1-year from the date of this publication, expiring on July 7, 2027.

ADDRESSES: This notification of enforcement discretion may be viewed online at *www.regulations.gov* using the docket numbers listed above. Electronic retrieval help and guidelines are available on the website. It is available 24 hours each day, 365 days each year. An electronic copy of this document may also be downloaded from the Office of the Federal Register's website at *www.federalregister.gov* and the Government Publishing Office's website at *www.GovInfo.gov.*

FOR FURTHER INFORMATION CONTACT: Clereece Kroha or Blane Workie, Office of Aviation Consumer Protection, U.S. Department of Transportation, 1200 New Jersey Avenue SE, Washington, DC 20590, 202–366–9342 (phone), 202–366–7152 (fax), *clereece.kroha@dot.gov,* or *blane.workie@dot.gov* (email).

SUPPLEMENTARY INFORMATION: On April 26, 2024, DOT published a final rule titled ''Refunds and Other Consumer Protections'' (Refund I) (89 FR 32760). Under that rule, a ''cancelled flight'' was defined in a way that classified a flight operated under a different flight number as a new flight, meaning the original flight was considered cancelled and subject to refund requirements. The rule also requires carriers to provide notifications to affected consumers that they are entitled to a refund when a flight cancellation or significant delay or change occurs. Following the implementation of Refund I, multiple airlines submitted requests highlighting the necessity of flight renumbering for logistical reasons (such as switching between mainline and regional service) and the general lack of material impact on passengers. Upon review, DOT determined that consumers face no inherent harm from routine flight renumbering, and, on December 5, 2025, published a notification of enforcement discretion (90 FR 55999) announcing no enforcement of these specific ticket refund and notification requirements until June 30, 2026.

The Department is engaged in a rulemaking titled ''Airline Refunds and Other Consumer Protections III'' (Refund III), identified by RIN 2105–AF36. Among other things, this proposed rule aims to reduce unnecessary regulatory burdens by modifying the definition of a flight cancellation that would entitle consumers to ticket refunds. Because the Refund III rulemaking remains pending, the Department is extending the enforcement pause for an additional 1-year period from the date of this publication. Taking this interim step avoids imposing counterproductive operational and technical difficulties on airlines while the rulemaking process is ongoing.

This enforcement discretion remains temporary and strictly limited. It applies solely to situations where a flight is given a different flight number but the passenger is successfully rebooked on

the new flight without experiencing a ''significant change or delay'' (*e.g.,* changes to departure/arrival times by three or more hours domestically, changes in departure/arrival airports, or downgrades in class of service). If a flight number change is accompanied by any such significant delay or disruptions, standard consumer refund mandates remain fully enforceable.

This extension does not prejudge the outcome of the pending Refund III rulemaking. Furthermore, it does not alter any other consumer protections established in other DOT rulemakings, including airlines' obligations to offer free rebooking when a change to a smaller aircraft means a passenger's wheelchair or scooter can no longer be accommodated. It also does not alter how U.S. carriers report on-time performance data to the Department pursuant to 14 CFR part 234.

Issued in Washington, DC, under authority delegated in 49 CFR 1.27(n):

Gregory Zerzan,

General Counsel.

[FR Doc. 2026–13675 Filed 7–6–26; 8:45 am]

BILLING CODE 4910–9X–P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

21 CFR Parts 516, 520, 522, 524, 529, 556, and 558

[Docket No. FDA–2026–N–0002]

New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of Sponsor

AGENCY: Food and Drug Administration, HHS.

ACTION: Final rule; technical amendments.

SUMMARY: The Food and Drug Administration (FDA or we) is amending the animal drug regulations to reflect application-related actions for new animal drug applications (NADAs), abbreviated new animal drug applications (ANADAs), and conditionally approved new animal drug applications (CNADAs) during January, February, and March 2026. The animal drug regulations are also being amended to improve their accuracy and readability.

DATES: This rule is effective July 7, 2026.

FOR FURTHER INFORMATION CONTACT: James Delaney, Center for Veterinary Medicine, Food and Drug Administration, 5001 Campus Dr., College Park, MD 20740, *James.Delaney@fda.hhs.gov,* 240–402–5677.

SUPPLEMENTARY INFORMATION:

I. Approval of Applications

FDA is amending the animal drug regulations to reflect approval actions for NADAs, ANADAs, and CNADAs during January, February, and March 2026, as listed in table 1. Documentation of environmental review required under the National Environmental Policy Act, summaries of the basis of approval under the Freedom of Information Act (FOIA summaries), and marketing exclusivity and patent information are available at Animal Drugs @FDA: *https://animaldrugsatfda.fda.gov/adafda/views/#/search.*

TABLE 1—ORIGINAL, CONDITIONAL, AND SUPPLEMENTAL APPLICATIONS APPROVED DURING JANUARY, FEBRUARY, AND MARCH 2026

Date of approval	Application No.	Sponsor (drug labeler code [1])	Product name	Effect of the action	21 CFR sections
December 4, 2025	141–167	Intervet, Inc. (000061)	EXZOLT CATTLE–CA (fluralaner topical solution).	Conditional approval	516.900 556.290(b)(2)
January 9, 2026	200–828	Parnell Technologies Pty. Ltd. (068504).	nixiFLOR (florfenicol and flunixin meglumine) injectable solution.	Original approval as a generic copy of NADA 141–299.	522.956
January 9, 2026	141–615	Pegasus Laboratories, Inc. (055246).	KBROVET (potassium bromide chewable tablets).	Original approval	516.1858 520.1858
January 12, 2026	200–833	Felix Pharmaceuticals Pvt. Ltd. (086101).	Maropitant Citrate Chewable Tablets.	Original approval as a generic copy of NADA 141–262.	520.1315
January 13, 2026	200–831	Norbrook Laboratories Ltd.	Defendazole (fenbendazole)	Original approval as a generic copy of RLNAD NADA 128–620.	520.905a
January 13, 2026	141–518	Intervet, Inc. (000061)	BRAVECTO PLUS (fluralaner and moxidectin topical solution).	Supplemental approval	524.1001
January 15, 2026	141–575	Boehringer Ingelheim Animal Health USA, Inc. (000010).	VETMEDIN Solution (pimobendan oral solution).	Supplemental approval	520.1782
January 20, 2026	141–554	Boehringer Ingelheim Animal Health USA, Inc. (000010).	NEXGARD PLUS (afoxolaner, moxidectin, and pyrantel chewable tablets).	Supplemental approval	520.35
January 29, 2026	200–761	Cronus Pharma Specialities India Private Ltd. (069043).	Cronoquin Tablets (marbofloxacin tablets).	Original approval as a generic copy of NADA 141–151.	520.1310
January 30, 2026	200–830	Parnell Technologies Pty. Ltd. (068504).	Sevoflurane (sevoflurane)	Original approval as a generic copy NADA 141–103.	529.2110
February 6, 2026	200–838	Felix Pharmaceuticals Pvt. Ltd. (086101).	Atipamezole Hydrochloride Injection (atipamezole hydrochloride) sterile injectable solution.	Original approval as a generic copy of NADA 141–033.	522.147
February 23, 2026	200–822	Baxter Healthcare Corporation (010019).	ANIRANE (isoflurane)	Original approval as a generic copy of NADA 135–773.	529.1186
February 23, 2026	200–841	Felix Pharmaceuticals Pvt. Ltd. (086101).	Firocoxib Tablets for Horses (firocoxib).	Original approval as a generic copy of NADA 141–458.	520.928
March 9, 2026	200–804	Cronus Pharma Specialities India Private Ltd. (069043).	Robenacoxib Injection (robenacoxib) Injectable Solution.	Original approval as a generic copy of NADA 141–443.	522.2075
March 10, 2026	095–735	Elanco, US Inc, (058198)	Rumensin 113 (monensin Type A medicated article).	Supplemental approval	558.355
March 16, 2026	141–599	Intervet, Inc. (000061)	BRAVECTO QUANTUM (fluralaner for extended-release injectable suspension).	Supplemental approval	522.998
March 23, 2026	141–616	Zoetis (054771)	DECTOMAX -CA1 (doramectin injection).	Supplemental approval	516.570

[1] See 21 CFR 510.600(c) for sponsor addresses.